IDWeek 2019 — BioFire CNS assay decreases use of lumbar punctures


  • Devona Williams, Pharm.D.
  • Actualités des congrès
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • Rapid identification of central nervous system (CNS) pathogens with BioFire Meningitis Enchephalitis PCR assay can help prevent repeat lumbar punctures (LP).

Why this matters

  • Patients admitted to a hospital with symptoms of meningitis or encephalitis are at risk for adverse clinical outcomes.
  • Faster diagnosis and confirmation of CNS organisms can prevent repeat LP and decrease unnecessary antimicrobial therapies.

Study design

  • Retrospective review initiated by clinical staff.
  • Cerebrospinal fluid (CSF) samples were obtained from the microbiology laboratory from patients who had been admitted with symptoms of meningitis or encephalitis.
  • Testing was performed on CSF specimens that had not been centrifuged via BioFire FilmArray Meningitis Encephalitis PCR assay.
  • Funding: None.

Key results

  • Pediatric and adult patients were included for analysis (27.1% and 72.8%).
  • Repeat LP required: 21.4%.
  • Median time to repeat LP: 4 days.
  • Median time to BioFire organism diagnosis: 26 hours.
  • Patients with negative BioFire were often prescribed antiviral and antibiotic therapy (47.8% and 97.8%).
  • BioFire identified a pathogen in 33.3% of patients with a discharge diagnosis of unknown etiology using conventional methods.

Limitations

  • Single-center review.
  • Results presented at a conference and not peer-reviewed.